0001415889-24-024813.txt : 20241007 0001415889-24-024813.hdr.sgml : 20241007 20241007160422 ACCESSION NUMBER: 0001415889-24-024813 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20241003 FILED AS OF DATE: 20241007 DATE AS OF CHANGE: 20241007 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dierks Jeffrey CENTRAL INDEX KEY: 0001821102 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39450 FILM NUMBER: 241357811 MAIL ADDRESS: STREET 1: 630 W. GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc. CENTRAL INDEX KEY: 0001802665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822279923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: (484) 539-9800 MAIL ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 4 1 form4-10072024_081018.xml X0508 4 2024-10-03 0001802665 Harmony Biosciences Holdings, Inc. HRMY 0001821102 Dierks Jeffrey C/O HARMONY BIOSCIENCES HOLDINGS, INC. 630 W GERMANTOWN PIKE, SUITE 215 PLYMOUTH MEETING PA 19462 false true false false CHIEF COMMERCIAL OFFICER 0 Common Stock 2024-10-03 4 S 0 35652 35.0453 D 705 D Common Stock 2024-10-03 4 S 0 705 35.6191 D 0 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.58 to $35.57. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.59 to $35.69. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Christian Ulrich, Attorney-in-Fact 2024-10-07